Table 4. Meta-analysis of the rs3802842 in association with colorectal cancer riska.
| Genetic model | OR (95% CI) | P | I 2 (%) | P heterogeneity | P for Egger’s test | |
| Overall | ||||||
| Overall (n = 25) | C VS. A | 1.15 (1.11–1.19) | 0.000 | 49.6% | 0.003 | 0.533 |
| Overall (n = 24) | AC VS. AA | 1.18 (1.12–1.24) | 0.000 | 46.3% | 0.007 | 0.216 |
| CC VS. AA | 1.31 (1.20–1.42) | 0.000 | 51.3% | 0.002 | 0.968 | |
| Dominant model | 1.20 (1.15–1.26) | 0.000 | 54.0% | 0.001 | 0.283 | |
| Recessive model | 1.20 (1.12–1.29) | 0.000 | 37.2% | 0.036 | 0.818 | |
| Additive model | 1.15 (1.11–1.19) | 0.000 | 47.2% | 0.006 | 0.568 | |
| Overall (n = 31) | Additive modelb | 1.15 (1.11–1.19) | 0.000 | 43.2% | 0.006 | 0.499 |
| Ethnicity | ||||||
| European (n = 21) | C VS. A | 1.14 (1.11–1.18) | 0.000 | 8.4% | 0.349 | 0.934 |
| European (n = 20) | AC VS. AA | 1.15 (1.11–1.20) | 0.000 | 0.0% | 0.457 | 0.665 |
| CC VS. AA | 1.30 (1.20–1.40) | 0.000 | 20.9% | 0.195 | 0.482 | |
| Dominant model | 1.18 (1.14–1.22) | 0.000 | 0.0% | 0.467 | 0.841 | |
| Recessive model | 1.21 (1.12–1.31) | 0.000 | 24.5% | 0.155 | 0.432 | |
| Additive model | 1.13 (1.09–1.17) | 0.000 | 29.3% | 0.108 | 0.890 | |
| Asian (n = 4) | C VS. A | 1.20 (1.02–1.38) | 0.000 | 88.1% | 0.000 | 0.443 |
| AC VS. AA | 1.33 (1.07–1.66)c | 0.011 | 86.6% | 0.000 | 0.210 | |
| CC VS. AA | 1.39 (1.03–1.87)c | 0.033 | 87.1% | 0.000 | 0.518 | |
| Dominant model | 1.35 (1.06–1.71)c | 0.014 | 90% | 0.000 | 0.272 | |
| Recessive model | 1.16 (0.97–1.39)c | 0.100 | 71% | 0.016 | 0.801 | |
| Additive model | 1.22 (1.09–1.36) | 0.000 | 73.2% | 0.011 | 0.428 | |
| Study type | ||||||
| GWAS (n = 3) | C VS. A | 1.20 (1.14–1.27) | 0.000 | 0.0% | 0.948 | 0.204 |
| AC VS. AA | 1.17 (1.09–1.26) | 0.000 | 0.0% | 0.571 | 0.535 | |
| CC VS. AA | 1.49 (1.33–1.68) | 0.000 | 0.0% | 0.463 | 0.428 | |
| Dominant model | 1.22 (1.14–1.31) | 0.000 | 0.0% | 0.882 | 0.607 | |
| Recessive model | 1.40 (1.23–1.59) | 0.000 | 21.3% | 0.281 | 0.453 | |
| Additive model | 1.20 (1.14–1.26) | 0.000 | 0.0% | 0.903 | 0.275 | |
| Replication (n = 22) | C VS. A | 1.14 (1.10–1.19) | 0.000 | 50.2% | 0.004 | 0.376 |
| Replication (n = 21) | AC VS. AA | 1.18 (1.13–1.24) | 0.000 | 52.1% | 0.003 | 0.163 |
| CC VS. AA | 1.27 (1.16–1.39) | 0.000 | 48.5% | 0.007 | 0.798 | |
| Dominant model | 1.20 (1.13–1.28) | 0.000 | 59.0% | 0.000 | 0.190 | |
| Recessive model | 1.15 (1.08–1.24) | 0.000 | 21.0% | 0.190 | 0.936 | |
| Additive model | 1.14 (1.09–1.19) | 0.000 | 48% | 0.008 | 0.380 | |
| Subjects with/without Lynch syndrome | ||||||
| With Lynch syndrome (n = 3) | C VS. A | 1.22 (1.08–1.35) | 0.000 | 0.0% | 0.589 | 0.355 |
| Without Lynch syndrome (n = 22) | C VS. A | 1.16 (1.11–1.20) | 0.000 | 56.2% | 0.001 | 0.525 |
| AC VS. AA | 1.18 (1.12–1.24) | 0.000 | 50.3% | 0.004 | 0.167 | |
| CC VS. AA | 1.31 (1.20–1.43) | 0.000 | 55.5% | 0.001 | 0.957 | |
| Dominant model | 1.21 (1.15–1.27) | 0.000 | 57.6% | 0.000 | 0.224 | |
| Recessive model | 1.20 (1.12–1.29) | 0.000 | 42.5% | 0.019 | 0.860 | |
| Additive model | 1.15 (1.11–1.19) | 0.000 | 51.5% | 0.003 | 0.492 |
a
Crude ORs were combined in a fixed- or random- effects model.
b
Both crude and adjusted ORs were combined.
c
The association between rs3802842 and colorectal cancer risk turned to be null significant after Bonferroni correction for multiple testing was applied.